1/10 Delighted that our study using pharmacogenomics to find compounds promoting oligodendrogenesis and repair in myelin pathologies is now published in Nat Communs, after 7 years of work! rdcu.be/dZ89J (DOI: 10.1038/s41467-024-54003-9)
9/10 These findings support the repurposing of leucovorin and dyclonine for clinical trials targeting myelin disorders, offering potential therapeutic avenues for preterm brain injury and Multiple Sclerosis
10/10 Many thanks to all contributors from @TheHassanLab, @InstitutCerveau, our collaborators from Olivier Raineteau lab and funders (ANR NeoRepair & ANR NeoReGen, @France_SEP, BDL Capital Management)
Carlos.Parras.Team retweeted
We invite you to become member and register for free on the website italianglianetwork.wixsite.c…, involving colleagues who may be interested in this initiative
Carlos.Parras.Team retweeted
Our latest paper out by @merbengochea @TheHassanLab about the numerical cognitive abilities of flies and the first evidence for the neurons required for this capacity in the visual system
"Numerical discrimination in Drosophila melanogaster"
@InstitutCerveau Laurent Cohen, @bassemh1
Read more in @CellReports cell.com/cell-reports/fullte…
Carlos.Parras.Team retweeted
Et si la maladie d’#Alzheimer imprimait sa marque chez l’embryon ? Des scientifiques de l’@InstitutCerveau (@inserm), montrent que la protéine précurseur de l’amyloïde (APP) possède un rôle biologique spécifique lors du neurodéveloppement.
institutducerveau-icm.org/fr…
Carlos.Parras.Team retweeted
@ShabaniDania @TheHassanLab @InstitutCerveau @ParisBrainInst paper on how the APP protein-famous for its role in Alzheimer’s disease- is actually a regulator of the tempo of human cortical development is now out in @ScienceAdvances
science.org/doi/10.1126/scia…
Carlos.Parras.Team retweeted
June 20th in Paris: 'The Times of Embryonic Development’ A symposium at Collège de France @cdf1530. Open, no registration, super speakers 👇🏼@PourquieO @DesplanLab @briscoejames @EbisuyaMiki @VanderhaeghenP2 @maitrejl @Anissakempf @gregorscience @the_Node @LecuitLab
Carlos.Parras.Team retweeted
braincouncil.eu/pledge-for-s… European Parliament is about to discuss a complete ban for animal research. This is real and will be catastrophic for progress in the fight against many diseases. Please support @EU_Brain pledge:
Carlos.Parras.Team retweeted
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:
ALT Neuroitic plaque (stained green) surrounded by dystrophic neurites (faint red) and microglia (brighter red). SchragLAB
I am delighted to tell you that our paper on Tensin3 is now available as html version in eLife doi.org/10.7554/eLife.80273, with a great layout and lots of shared data files. Thanks a lot to all the people involved! particularly to @EmericMerour and @TheHassanLab at @ParisBrainInst
I am glad to share with you our last study on Tensin3 and oligodendrocyte differentiation summarizing 8 years of work by @EmericMerour & Hatem Hmidan and collaborators at the @ParisBrainInst biorxiv.org/content/10.1101/….
As promised @GordonConf#Myelin here is the revised version after Review Commons peer-review of our Tns3 paper, that has been submitted now to eLife. I hope you will appreciate the improvements.
biorxiv.org/content/10.1101/…